Comparing the current results to its competitors, Longboard Pharmaceuticals Inc reported Revenue decrease in the 3 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 19.56 %, recorded in the same quarter.
October 14, 2024
Lundbeck s Strategic Acquisition of Longboard Pharmaceuticals: A Pivotal Move in the Neuroscience Arena In a landmark transaction poised to significantly enhance its neuroscience pipeline, the Danish pharmaceutical giant Lundbeck A/S has announced its strategic acquisition of California-based Longboard Pharmaceuticals, Inc. This move marks a substantial investment in the evolving landscape of neurological therapies and underscores Lundbeck’s commitment to addressing the unmet medical needs associated with epilepsy and other neurological disorders. The deal, worth approximately USD 2.6 billion, demonstrates Lundbeck s proactive approach as it initiates a tender offer of USD 60.00 in cash per share for all o...
September 26, 2024
Longboard Pharmaceuticals Advances in Neurological Drug Development: Phase 3 DEEp SEA Study Initiated for BexicaserinLongboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company, has announced the initiation of its Phase 3 DEEp SEA Study. This global study will evaluate the efficacy and safety of its investigational drug, bexicaserin, for treating seizures associated with Dravet syndrome in participants aged two years and older. This announcement represents a significant milestone for the company and the potential future of treatment for Dravet syndrome. Overview of Bexicaserin Studies and Developments Phase 3 DEEp SEA Study for Dravet Syndrome Dravet syndrome is a rare, catas...
Publicly Traded Peers of Longboard Pharmaceuticals Inc
X4 Pharmaceuticals Inc Share Performance
+2.15%
One Year
X4 Pharmaceuticals Inc
Profile
X4 Pharmaceuticals Inc is a biopharmaceutical company focused on the research and development of innovative treatments for rare diseases, particularly those involving the immune system and rare genetic disorders. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials, and ultimately bringing these therapies to market to improve patient outcomes.
Sage Therapeutics Inc's business model primarily revolves around researching, developing, and commercializing innovative therapies for various central nervous system disorders. The company focuses on discovering novel molecules and applying them to create targeted treatments that address the unmet medical needs of patients. By harnessing scientific advancements and strategic collaborations, Sage aims to deliver transformative therapies for individuals suffering from conditions such as depression, postpartum depression, and other mood disorders.
Protagenic Therapeutics Inc has developed a novel business model focused on the discovery and development of novel therapeutics targeting the PGRMC1 receptor, which plays a crucial role in various diseases. By leveraging their proprietary technology and partnerships, the company aims to advance the development of innovative drugs that can effectively treat a range of conditions influenced by the PGRMC1 receptor.
Praxis Precision Medicines Inc's business model revolves around developing precision medicines for the treatment of various central nervous system (CNS) disorders.
Sources:
Longboard Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Longboard Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
